Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.41
-0.04 (-0.73%)
At close: Mar 6, 2026, 4:00 PM EST
5.32
-0.09 (-1.66%)
After-hours: Mar 6, 2026, 7:36 PM EST
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$4,119,357
Market Cap
175.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | 4 | 40.00% |
| Dec 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 3 | 42.86% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 166 |
| Nkarta | 105 |
| Vaxart | 105 |
| Tenaya Therapeutics | 97 |
| Tonix Pharmaceuticals Holding | 81 |
| Cartesian Therapeutics | 66 |
| SAB Biotherapeutics | 63 |
| Tiziana Life Sciences | 9 |
SGMT News
- 3 days ago - Sagimet Biosciences Inc. (SGMT) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 10 days ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
- 5 weeks ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
- 5 weeks ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
- 2 months ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire
- 2 months ago - Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market - Seeking Alpha